Miriam joined Sapreme as Chief Development Officer in late 2020. She is an experienced early clinical development leader with a background in antibody and RNA therapeutics. At Sapreme, she uses her translational science expertise to drive the development of innovative next-generation therapeutics that evade endosomal entrapment. Prior to Sapreme, she held various positions including Senior Director R&D at ProQR Therapeutics, where she led the translational and early clinical development of novel RNA therapeutics for inherited eye, skin and lung diseases. From 2012 to 2016, she held various positions including Principal Scientist Biomarker Development at the Janssen Pharmaceutical Companies of Johnson & Johnson. Here, she also served as a preclinical lead scientist on various anti-viral antibody therapy development programs from discovery up to Phase 2 clinical development. From 2010 to 2012, Miriam worked at Crucell in therapeutic antibody discovery. Miriam holds a Ph.D. in Biochemistry from the School of Medical Sciences,University of Bristol, and completed postdoctoral training with Prof. Xiaowei Zhuang at Harvard University in the Department of Chemistry and Chemical Biology.